EUCTR2013-000474-30-AT进行中（未招募）不适用
Antidotes that are potentially useful for reversal of new oral anticoagulants (NOACs) and new platelet inhibitors (NOPAIs)
Medizinische Universität Innsbruck / Univ.-Klinik für Allg. u. Chirurg. Intensivmedizin0 个研究点开始时间: 2013年3月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Patient with the clinical need for anticoagulation using NOACs or NOPAIs
- •? The steady state of the single drugs have already been achieved (plasma level)
- •? Age: 18-90 years
- •? Healthy patient with no clinical need for anticoagulation
- •? Medications that could interfere with the results of the study (e.g. Aspirin, other anticoagulants etc.) have to be completely eliminated from the proband’s body
- •? Age: 18-85 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •? Pregnancy
- •? Patients who disagree to participate in the study
- •? Incompliant patients in taking medication (poor compliance) )
- •? Concomitant medication with influence on the respective anticoagulant and/or platelet activity
- •? Presence of any kind of haemophilia or acquired and hereditary coagulation disorders
- •? Active participation in another clinical trial
- •? Any condition, including the presence of laboratory abnormalities, that could prevent correct interpretation of the achieved data
- •? Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
- •? Patients who disagree to participate in the study
- •? Concomitant medication with influence on anticoagulant and/or platelet activity (e.g. Aspirin, other anticoagulants etc.)
- •? Presence of any kind of haemophilia or acquired and hereditary coagulation disorders
- •? Active participation in a clinical trial
- •? Any condition, including the presence of laboratory abnormalities, that could prevent correct interpretation of the achieved data
- •? Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
研究者
相似试验
招募中
不适用
Pharmaceutical-pharmacological interventions to improve drug therapy safety of inpatient carelow adherence, problems with drug application/use, patients' concerns regarding their drug therapyDRKS00026088Abteilung Klinische Pharmakologie und Pharmakoepidemiologie, Medizinische Klinik100
招募中
不适用
Clinical alternatives for greater efficiency of home whitening. Effects of using trays with and without reservoirsTooth Discoloration, Dentin sensitivityC07.793.735C07.793.266RBR-2hyztpFaculdade de Odontologia de Araçatuba
进行中（未招募）
1 期
Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial – eCLEAREUCTR2015-002234-53-DKDepartment of Infectious Diseases, Aarhus University Hospital60
进行中（未招募）
1 期
Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial – eCLEARHIV persistence during initiation of antiretroviral therapyMedDRA version: 20.1 Level: LLT Classification code 10073675 Term: HIV infection CDC category unspecified System Organ Class: 100000004862EUCTR2015-002234-53-GBDepartment of Infectious Diseases, Aarhus University Hospital60
进行中（未招募）
1 期
The effect of drugs used to reverse neuromuscular blockade on intra-cranial pressure - Reversal and ICPEUCTR2009-011696-68-GBniversity of Nottingham40